Misyo (Methadone Hydrochloride)

Methadone acts as a full agonist at the mu‑opioid receptor, binding with high affinity to produce analgesia and suppress withdrawal. It also blocks NMDA receptors and inhibits reuptake of serotonin and norepinephrine, which contributes to its effectiveness in chronic pain and opioid substitution.

The appropriate dose of Misyo is individualized and determined by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made under medical supervision to achieve therapeutic goals while minimizing risk.

Methadone can be used during pregnancy when the benefits outweigh potential risks, as abrupt discontinuation may cause fetal harm. However, it crosses the placenta and is excreted in breast milk, so clinicians must assess each case carefully and monitor both mother and infant closely.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with shorter‑acting opioids such as morphine, methadone has a longer half‑life, allowing once‑daily dosing for maintenance therapy. Its additional NMDA antagonism may provide benefit in neuropathic pain, but it also requires careful cardiac monitoring due to QT‑interval effects, which is less prominent with many other opioids.

Misyo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Misyo is administered orally, typically as a tablet or liquid formulation. The exact dosage form is determined by the prescriber, who instructs the patient on the appropriate amount and frequency, usually once daily for maintenance therapy.

The most serious risks include respiratory depression, which can be fatal if not recognized promptly, and cardiac arrhythmias due to QT‑interval prolongation. Both risks are heightened during treatment initiation, dose escalation, or when interacting with other CNS depressants or QT‑prolonging drugs.

Misyo is contraindicated in individuals with known hypersensitivity to methadone or any component of the formulation, in patients with severe respiratory insufficiency, and in those with uncontrolled cardiac arrhythmias or a history of prolonged QT interval. It should also be avoided in patients taking certain interacting medications without close medical supervision.